RIFAXIMIN 400mg. IP

A broad-spectrum antibiotic with antimicrobial activity against gram-positive and gram-negative aerobic and anaerobic pathogens. (Rani H Shayto, 2016) Possesses good activity against species of Staphylococcus, Streptococcus, and Enterococcus. (J C Gillis, 1995) A potential therapeutic agent for the treatment of gastrointestinal and liver conditions. (Rani H Shayto R. A., 2016) A safe antibiotic for gut microbiota modulation in patients with irritable bowel syndrome. (Francesca Romana Ponziani, 2016) An important therapeutic agent in several gastrointestinal diseases such as hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel disease, and colonic diverticular disease. (Veronica Ojetti 1, 2009) Improves gastrointestinal symptoms, quality of life in irritable bowel syndrome with diarrhea patients. (Xiaojun Zhuang, 2020) Significantly ameliorates health-related quality of life in patients with cirrhosis and recurrent hepatic encephalopathy. (Rani H Shayto, 2016) A safe and effective alternative to ciprofloxacin in the treatment of traveler's diarrhea. (HL DuPont 1, 2001) Effectively shortens the duration of travelers’ diarrhea without important alteration of colonic flora. (Zhi-Dong Jiang, 2010) Shows superior efficacy compared with lactulose, similar efficacy to paromomycin, neomycin in the treatment of hepatic encephalopathy. (Darego O Maclayton, 2009)